B
BIOVIE INC.
BIVICIK 0001580149NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsNevadaFY ends Jun 30
Period
FY 2025
Revenue
—
Net Income
$-17.54M
Total Assets
$21.56M
Equity
$19.01M
Shares Out
7.54M
Op. Cash Flow
$-19.03M
Business
BioVie Inc. is a clinical-stage pharmaceutical company developing novel drug therapies for neurological and neurodegenerative disorders and advanced liver disease. The company's lead program, bezisterim (NE3107), is an orally administered small-molecule anti-inflammatory insulin-sensitizer in Phase 2/3 development for Alzheimer's disease, Parkinson's disease, and long COVID. BioVie's secondary program, BIV201 (continuous infusion terlipressin), is a proprietary liquid formulation in Phase 2 development for ascites and complications of liver cirrhosis. The company operates as a clinical-stage developer with no approved products currently marketed.
Summary from 10-K filed 2025-08-15
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Amortization of intangible assets | 229,377 | 229,377 | 229,377 | 229,377 | 229,377 | |
| Research and development expenses | 9 | 23 | 33 | 17 | 3 | |
| Selling, general and administrative expenses | 9 | 9 | 12 | 10 | 5 | |
| TOTAL OPERATING EXPENSES | 18 | 32 | 45 | 27 | 138 | |
| LOSS FROM OPERATIONS | −18 | −32 | −45 | −27 | −138 | |
| Change in fair value of derivative liabilities | −3,771 | −2 | 1 | −3 | −8 | |
| Interest expense | 332,720 | 3 | — | — | — | |
| Interest income | −853,029 | −1 | −562,264 | −44,080 | −21,971 | |
| TOTAL OTHER INCOME , NET | −524,080 | −59,052 | 5 | — | — | |
| NET LOSS | −18 | −32 | −50 | −26 | — | |
| Deemed dividend related to ratchet adjustment to warrants | 369,465 | 886,423 | — | — | — | |
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | −18 | −33 | −50 | −26 | −184 | |
| - Basic (per share) | −12.12 | −73.05 | −15.47 | −1.06 | −14.82 | |
| - Diluted (per share) | −12.12 | −73.05 | −15.47 | −1.06 | −14.82 | |
| - Basic (shares) | 1 | 451,853 | 3 | 25 | 12 | |
| - Diluted (shares) | 1 | 451,853 | 3 | 25 | 12 | |
| Reclassification of unrealized gains on available-for-sale investments upon settlement | — | −176,591 | — | — | — | |
| Total other comprehensive loss | — | −176,591 | 176,591 | — | — | |
| Comprehensive loss | −18 | −33 | −50 | −26 | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2024 2024-01-31 | FY 2023 2023-06-30 | FY 2022 2022-06-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 18 | 24 | — | 19 | 19 | |
| Grant receivable | 2 | — | — | — | — | |
| Prepaid and other current assets | 1 | 204,392 | — | — | — | |
| Total current assets | 21 | 24 | — | 34 | 19 | |
| Operating lease right-of-use asset, net | 339,653 | 406,726 | 56,909 | 80,789 | 118,254 | |
| Intangible assets, net | 178,341 | 407,718 | — | 637,095 | 866,472 | |
| Goodwill | 345,711 | 345,711 | — | 345,711 | 345,711 | |
| TOTAL ASSETS | 22 | 25 | — | 35 | 20 | |
| Accounts payable and accrued expenses | 2 | 4 | — | 3 | 2 | |
| Current portion of operating lease liability | 74,464 | 60,343 | — | 44,909 | 38,884 | |
| Current portion of notes payable, net of financing cost, unearned premium and discount of $701,210 at June 30, 2024 | — | 6 | — | 9 | — | |
| Warrant liability | — | 3,771 | — | 894,280 | 194,531 | |
| Total current liabilities | 2 | 9 | — | 14 | 4 | |
| Operating lease liability, net of current portion | 275,430 | 349,894 | — | 42,505 | 87,414 | |
| TOTAL LIABILITIES | 3 | 10 | — | 20 | 16 | |
| Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding | — | — | — | — | — | |
| Common stock, $0.0001 par value; 800,000,000 shares authorized at June 30, 2025 and June 30, 2024; 1,917,061 shares issued of which 1,914,224 shares are outstanding at June 30, 2025; and 621,641 shares issued of which 619,008 shares outstanding at June 30, 2024 | 7,476 | 6,229 | — | 3,643 | 2,496 | |
| Additional paid in capital | 371 | 350 | — | 316 | 255 | |
| Accumulated deficit | −352 | −334 | — | −301 | −251 | |
| Treasury stock | −29 | −27 | — | −2 | — | |
| Total stockholders' equity | 19 | 16 | — | 15 | 4 | |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 22 | 25 | — | 35 | 20 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Stock based compensation - restricted stock units and restricted shares | 1 | 2 | 2 | 386,208 | — | |
| Stock based compensation expense - stock options | 1 | 3 | 4 | 6 | — | |
| Stock based compensation expense - issuance of common stock for services rendered | 73,680 | 72,900 | — | — | — | |
| Amortization of financing costs | 11,820 | 108,751 | 170,219 | 99,295 | — | |
| Accretion of unearned loan discount | 111,212 | 1 | 2 | — | — | |
| Accretion of loan premium | 25,758 | 236,970 | 421,994 | 165,278 | — | |
| Realized gain on maturity of available-for sale | — | −223,865 | — | — | — | |
| Non-cash lease expense from right-of-use assets | 67,073 | 49,346 | 37,465 | — | — | |
| Gain on termination of operating lease | — | −5,215 | — | — | — | |
| Change in fair value of derivative liabilities | −3,771 | −2 | 1 | −3 | −8 | |
| Grant receivable | −2 | — | — | — | — | |
| Prepaid and other current assets | −845,505 | −101,866 | 39,915 | −48,954 | — | |
| Accounts payable and accrued expenses | −1 | 110,653 | 1 | 1 | −262,832 | |
| Operating lease liabilities | −60,343 | −47,245 | −38,884 | — | — | |
| Other current liabilities | — | −48,385 | −1 | 1 | — | |
| Net cash used in operating activities | −19 | −28 | −40 | −19 | −10 | |
| Proceeds from U.S. Treasury Bills (available-for-sale) | — | 15 | −14 | — | — | |
| Net cash provided by investing activities | — | 15 | −14 | — | — | |
| Net proceeds from issuance of common stock | 16 | 28 | 49 | 19 | 16 | |
| Proceeds from exercise of warrants | 3 | −10 | — | — | — | |
| Payment of loan premium | −850,000 | — | — | — | — | |
| Payments of note payable | −5 | — | — | — | — | |
| Net cash provided by financing activities | 13 | 18 | 55 | 33 | 15 | |
| Net change in cash and cash equivalents | −6 | 4 | 819,167 | 14 | 4 | |
| Cash paid for interest | 183,930 | 2 | 2 | 964,241 | 22,180 | |
| Right of use assets obtained in exchange for lease obligations | — | 432,192 | — | 130,039 | — | |
| Deemed dividend for ratchet adjustment to warrants | 369,465 | 886,423 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is BIOVIE INC.'s CIK number?
BIOVIE INC.'s SEC CIK number is 0001580149 (1580149). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find BIOVIE INC.'s SEC filings?
All of BIOVIE INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.